Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLA: Relacorilant in Gynecological Cancers
NCT06906341Phase 2Recruiting
- Sponsor
- Corcept Therapeutics
- Start
- Apr 2025
- Primary completion
- Aug 2026
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 2 trial of relacorilant in ovarian cancer, fallopian tube cancer (PFTC), peritoneal neoplasms, endometrial cancer (EC), sponsored by Corcept Therapeutics. Started Apr 2025; status: recruiting.
02
Drugs
relacorilant
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)peritoneal neoplasmsendometrial cancer (EC)
Beyond the preview
Go deeper on NCT06906341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06906341.